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Malaria remains a world-threatening disease largely because of the lack of a long-lasting and fully effective vaccine. MAEBL is a
type 1 transmembrane molecule with a chimeric cysteine-rich ectodomain homologous to regions of the Duffy binding-like
erythrocyte binding protein and apical membrane antigen 1 (AMA1) antigens. AlthoughMAEBL does not appear to be essential
for the survival of blood-stage forms, ectodomains M1 andM2, homologous to AMA1, seem to be involved in parasite attach-
ment to erythrocytes, especially M2. MAEBL is necessary for sporozoite infection of mosquito salivary glands and is expressed in
liver stages. Here, the Plasmodium yoeliiMAEBL-M2 domain was expressed in a prokaryotic vector. C57BL/6J mice were immu-
nized with doses of P. yoelii recombinant protein rPyM2-MAEBL. High levels of antibodies, with balanced IgG1 and IgG2c sub-
classes, were achieved. rPyM2-MAEBL antisera were capable of recognizing the native antigen. Anti-MAEBL antibodies recog-
nized different MAEBL fragments expressed in CHO cells, showing stronger IgM and IgG responses to the M2 domain and
repeat region, respectively. After a challenge with P. yoelii YM (lethal strain)-infected erythrocytes (IE), up to 90% of the immu-
nized animals survived and a reduction of parasitemia was observed. Moreover, splenocytes harvested from immunized animals
proliferated in a dose-dependent manner in the presence of rPyM2-MAEBL. Protection was highly dependent on CD4, but not
CD8, T cells toward Th1. rPyM2-MAEBL antisera were also able to significantly inhibit parasite development, as observed in ex
vivo P. yoelii erythrocyte invasion assays. Collectively, these findings support the use of MAEBL as a vaccine candidate and open
perspectives to understand the mechanisms involved in protection.
Malaria remains one of the most devastating infectious dis-eases in intertropical countries, affecting mainly children
under the age of 5 years and pregnant women. Approximately
600,000 deaths occur every year (1). People repeatedly exposed to
malarial infections in areas where malaria is endemic develop im-
munity to clinical disease and subsequently to parasitemia (2–5).
Antibodies have been shown to be responsible for naturally ac-
quired immunity, since passive transfer of immune IgG from
adults can protect against Plasmodium falciparum blood-stage in-
fection (2, 6–8), suggesting that a malaria vaccine based on asexual
antigens is feasible. Unfortunately, none of the vaccines currently
tested achieved a convincing rate of protected individuals (9–11)
and the observed protection was often short-lived or highly strain
specific (12–16).
The stakes for blood-stage vaccines are even higher when ma-
laria eradication is the goal because the vaccines must not only
reduce disease but also reduce the parasitic burden to a degree that
reduces transmission (17). Despite considerable efforts, none of
the blood-stage vaccine candidates have exhibited satisfactory
clinical and sterile protection in field tests (18, 19).
Many of the current vaccine candidates were encountered on
the basis of the finding that partly immune individuals possess
high titers of antibodies against the antigens tested. Recently, the
finding that antibodies against PfRH5 are highly effective in
blocking merozoite reinvasion but are rarely detected in signifi-
cant quantities in semi-immune carriers was reported (20). This
suggests that other merozoite-exposed antigens to which no sig-
nificant response is developed in natural infections may also be
effective as vaccines.
MAEBL is a 200-kDa type 1 membrane protein that belongs to
the erythrocyte binding protein (ebl) family (21–24). It has a car-
boxy-terminal cysteine-rich region homologous to region IV of
the Duffy binding-like (DBL) erythrocyte binding protein. Addi-
tionally, the MAEBL amino-terminal cysteine-rich domains (M1
and M2 ligand domains) exhibit partial similarity to apical mem-
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brane antigen 1 (AMA1) (23, 25). The M1 and M2 domains of P.
yoelii have been shown to be functionally equivalent to the DBL
ligand domain, as they bind to mouse erythrocytes (25).
MAEBL is essential for the development of the parasite dur-
ing sporozoite infection of mosquito salivary glands (26, 27)
and is also expressed in the salivary gland sporozoite and dur-
ing the late liver stage (28). Weak expression of MAEBL can
also be detected in blood-stage merozoite forms, although
maebl deletion has no impact on blood-stage parasite develop-
ment (26). Coincidently, only few antibodies are found in natu-
rally infected individuals from areas with low transmission rates
(29). The gene for MAEBL is highly conserved between evolution-
arily distinct Plasmodium species (25). Among the clones of P.
falciparum and field isolates, there is little amino acid sequence
variation in the M1 and M2 domains (21). Because the gene for
MAEBL is well conserved and expressed at different parasite
stages, MAEBL is considered an interesting potential vaccine can-
didate (30).
The current knowledge of the mechanisms of and interactions
during Plasmodium invasion of erythrocytes is still limited, which
impairs the development of ways to block this essential step in
Plasmodium biology. As blocking of erythrocyte invasion strate-
gies is part of the rationale for several vaccines based on merozoite
antigens, approaches designed to elucidate the invasion phenom-
enon might facilitate the validation and identification of potential
antigens that could be used as vaccine targets.
In this study, we investigated the immunogenicity of the
MAEBL M2 domain of P. yoelii. We amplified, cloned, and ex-
pressed the MAEBL M2 domain as a prokaryotic fusion protein
(rPyM2-MAEBL). Mice received four doses of the recombinant
antigen emulsified in Freund’s adjuvant. Immunization induced
robust protection against a lethal challenge with asexual forms of
P. yoelii YM. Protection was dependent on CD4, but not CD8,
T cells toward Th1. By adapting an ex vivo invasion assay, we could
show that sera from immunized mice inhibited invasion of para-
site blood-stage forms. These results demonstrate that MAEBL
can be used as an antigen in antimalarial vaccine formulations.
MATERIALS AND METHODS
Parasites and animals. Six- to 7-week-old C57BL/6J mice were purchased
from the University of Campinas Animal Center (CEMIB-UNICAMP).
Animals were kept in a mouse pathogen-free facility. All experiments and
procedures were approved by the Ethical Committee for Animal Research
of the University of Campinas (protocol no. 1437-1). Blood forms of P.
yoelii were obtained after the intraperitoneal (i.p.) injection of thawed,
glycerin-frozen stocks.
Generation of the recombinant P. yoeliiMAEBL M2 domain. DNA
fragments encoding the MAEBL M2 domain were obtained by PCR am-
plification with Platinum Taq high-fidelity DNA polymerase (Invitrogen)
with P. yoelii genomic DNA from infected mice as a template. For ampli-
fication of the sequence corresponding to the M2 domain of the MAEBL
antigen, we used synthetic oligonucleotides based on the sequence of the
P. yoelii yoelii gene encoding amino acids 589 to 992 of MAEBL (GenBank
accession number AF031886). The wing oligonucleotides used for this
were pET28aM2F (5=-CGC GGA TCC CTT AAC AAA TAT ATG AAA
TCT AAT GTT GAA CTT-3=) and antisense pIgSPM2R (5=-CTC GAA
TTC CTA CGA TTC ATC GGT ATT TCT TGT AG-3=), which contain
BamHI and EcoRI sites and were purchased from Invitrogen. The result-
ing PCR product was purified and digested with both restriction enzymes
and inserted into the pET28a vector (Novagen). The resulting plasmid
was designated pET28aM2. To verify that the reading frame was correct,
inserts were sequenced with vector-specific oligonucleotides covering the
entire cloned sequence.
The recombinant protein (rPyM2-MAEBL) was expressed and puri-
fied as previously described (31), with slight modifications. E. coli
BL21(DE3) (Novagen) was transformed with the pET28aM2 plasmid and
cultivated at 37°C in Luria-Bertani broth in the presence of 30 g/ml
kanamycin (Sigma). Protein expression was induced at an optical density
at 600 nm (OD600) of 0.6 to 0.8 nm with 0.1 mM isopropyl--D-thioga-
lactopyranoside (Invitrogen) for 4 h. After centrifugation, the bacterial
pellet was resuspended and sonicated in phosphate-buffered saline (PBS)
supplemented with 1 mg/ml lysozyme (Sigma) and 100 mM phenylmeth-
ylsulfonyl fluoride (Sigma). The sonicated material was then centrifuged,
and the supernatant was separated from the pellet. Under these condi-
tions, rPyM2-MAEBL was found in the insoluble fraction. For solubiliza-
tion and purification, the pellet was resuspended in a mixture of 100 mM
Tris-HCl, 8 M urea, and 100 mM dithiothreitol at pH 8.0. Complete
solubilization was achieved by passage of the solution through a 21-gauge
needle. The solution was then centrifuged, and the supernatant was ap-
plied to a column with N2-nitrilotriacetic acid-agarose resin (Qiagen).
After extensive washing, the recombinant protein was eluted with a buffer
at pH 5.0 and the eluted protein was dialyzed against PBS with 2 M urea.
Protein expression and concentration were determined by SDS-PAGE
and immunoblotting analysis.
Generation of a pDisplay library containing fragments of the
MAEBL immunogen. Primers were designed to be in frame, comple-
mentary, and specific to different regions of MAEBL without self-
annealing sequences with the software Amplify3x. Three different re-
gions (MAEBL-3, MAEBL-4, and MAEBL-5) encompassing the M2,
repeat, and C-terminal cysteine regions, respectively, were designed. Six
smaller overlapping regions of the MAEBL-3 region (which contained
different segments of the M2 region, the interdomain between M2 and the
repeats, or the repeats) were designed and then subcloned into the pDis-
play vector (Invitrogen) together with MAEBL-4 and MAEBL-5 con-
structs. For the primer sequences used to clone these fragments of
MAEBL, see Table S1 in the supplemental material.
Genes of interest were amplified with Phusion Hot Start II polymerase
(Finnzymes) according to the manufacturer’s instructions by using the
Bio-Rad Peltier thermal cycler. The PCR products were ligated into the
XmaI- and SacII (NEB)-linearized pDisplay vector according to the man-
ufacturer’s recommendations (In-Fusion Cloning; Clontech) before heat
shock transformation into XL10-Gold bacteria (Agilent). Bacterial clones
were screened for positive transformants by colony PCR with T7 and BgH
primers. They were then sent for sequencing to ensure that the codons
were in frame. The plasmids were purified with the Nucleobond AX En-
dotoxin-Free Midiprep kit (Macherey-Nagel) before transfection. CHO
(Chinese hamster ovary) cells were used for the expression of recombi-
nant MAEBL proteins. Cells were grown in F12 complete medium con-
taining 100 U/ml penicillin (Gibco), 100 g/ml streptomycin (Gibco),
and 10% heat-inactivated fetal bovine serum (FBS) (Gibco) in a 37°C
incubator with 5% CO2. Sterile EDTA diluted to a final concentration of 2
mM in PBS was used to detach transfected cells/stable cell lines. Endo-
Fectin (GeneCopoeia) was used to transfect the recombinant pDisplay
plasmid into CHO cells. CHO cells were seeded into 6-cm cell culture
dishes 1 day before transfection at a density that would give approximately
70 to 80% confluence on the day of transfection. To transfect the cells, 9l
of EndoFectin was added dropwise with vortexing to 3 g of plasmid
diluted in F12 complete medium supplemented with 100 U/ml penicillin
and 100g/ml streptomycin for 6-cm dishes. The DNA-EndoFectin com-
plex was incubated at room temperature for 25 min before it was added
dropwise to the cells. The plates or dishes were swirled gently to distribute
the transfection mixture before being returned to the 37°C incubator
overnight. The transfection medium was replaced with fresh F12 com-
plete medium the following day.
Immunoblotting analysis. Recombinant protein samples were sub-
jected to SDS-PAGE under denaturing conditions (2-mercaptoethanol).
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Proteins were then transferred onto a nitrocellulose membrane (GE
Healthcare). Immunoblotting was conducted with an anti-His6 antibody
(Life Technologies) at a 1:1,500 dilution. Antibody binding was detected
by incubation with peroxidase-coupled goat anti-mouse IgG (Sigma) at a
1:2,000 dilution. Bands were detected with a solution containing 50 mM
Tris-HCl (pH 7.5), 0.6 mg/ml 3,3=-diaminobenzidine, and 1l/ml 0.03%
H2O2 (Sigma) solution.
Immunization regimen. Groups of 6 to 10 C57BL/6J male mice (6 to
7 weeks old) were injected subcutaneously four times at 3-week intervals
with 5g of rPyM2-MAEBL 1:1 (vol/vol) emulsified in complete Freund’s
adjuvant (CFA; Sigma) for the first dose or incomplete Freund’s adjuvant
(IFA) for the subsequent doses. As a control group, animals were injected
with 1:1 (vol/vol) adjuvant (CFA and IFA) in PBS. Sera were collected
from immunized mice immediately before each dose and 3 weeks after the
last dose (see Fig. 2A).
ELISA. Anti-rPyM2-MAEBL antibodies titers were determined by en-
zyme-linked immunosorbent assay (ELISA) as previously described (32).
Plates were coated with recombinant protein at 200 ng/well. Mouse sera
were tested at serial dilutions starting at 1:100. A 1:2,000 dilution of per-
oxidase-coupled goat anti-mouse IgG (Sigma) conjugated with Alexa
Fluor 568 was used as the secondary antibody. Specific anti-MAEBL titers
were determined as the highest dilution yielding an OD492 of 0.1. De-
tection of IgG subclasses was performed as described above, except that
the secondary antibody used was specific for mouse IgG1, IgG2b, and
IgG2c (Southern Technologies).
Epitope mapping. Transfected cells (150,000 per well) were tran-
siently transfected and seeded into 96-well plates (Nunc). They were
stained with serum diluted in fluorescence-activated cell sorter (FACS)
buffer (PBS plus 10% FBS) by incubation for 1 h with agitation at 4°C. The
different MAEBL constructs are flanked by a myc epitope at the N termi-
nus and a hemagglutinin (HA) epitope at the C terminus when expressed
on the CHO cell surface, and both epitopes were used to assess protein
expression on CHO cells with rabbit anti-myc IgG (Upstate) or rabbit
anti-HA IgG (Sigma) diluted 1:100. Untransfected parental CHO cells
were stained with the same sera and used as a negative control. For deter-
mination of serum recognition, the different test sera from mice immu-
nized with MAEBL protein or the control vehicle DMSO were diluted
1:100 and incubated with the cells for 1 h with agitation at 4°C and then
washed once with FACS buffer. The secondary antibody, either goat anti-
rabbit IgG-Alexa Fluor 488 (Molecular Probes, Invitrogen) diluted 1:500
for checking protein expression or goat anti-mouse IgM- or IgG-Alexa
Fluor 488 (Molecular Probes) diluted 1:500 and mixed with propidium
iodide diluted to 0.001 mg/ml for the serum screening assay, was incu-
bated for 30 min with agitation at 4°C. Labeled samples were analyzed
with the BD Accuri high-throughput flow cytometer (Becton Dickinson).
FlowJo (Tree Star Inc.) was used for all flow cytometry analysis. Serum
response was determined as the percentage of cells recognized by serum
divided by the percentage of cells expressing the construct of interest, as
illustrated in the following formula: Serum response  [(% of cells rec-
ognized by immune serum% of cells recognized by naive serum)/(% of
protein-of-interest-expressing cells)] 100%.
The 20% cutoff for positivity was determined as the mean plus 6 stan-
dard deviation of the quadruplicate serum recognition values obtained for
sera from naive animals. This high threshold was used to reduce the pos-
sibility of false-positive results.
Cellular proliferation and cytokine quantification. Ten million
splenic cells collected from animals in different immunization groups
(n  3) were cultured in a 96-well plate in a final volume of 200 l.
rPyM2-MAEBL protein was added to the culture at a final concentration
of 1 or 10g/ml. As a control, some wells received concanavalin A (ConA;
50 g/ml). Lymphocyte proliferation was assessed by the addition of
methyl-[3H]thymidine ([3H]TdR; GE Healthcare) at 0.5 mCi/well to the
splenocytes after 48 h of culture. Splenocytes were cultured for an addi-
tional 18 h, and plates were frozen. For later analysis, plates were thawed
and the culture was collected on filter paper with a cell harvester. Tritium
incorporation was measured as radioactivity with a 1450 MicroBeta Tri-
Lux scintillation and luminescence counter (PerkinElmer). The results
are expressed as the average of triplicate cultures.
In parallel, culture supernatants were collected after 120 h and the
amounts of secreted gamma interferon (IFN-	), tumor necrosis factor
(TNF), interleukin-2 (IL-2), IL-4, and IL-5 were simultaneously detected
with the BD Cytometric Bead Array (CBA) Mouse Th1/Th2 Cytokine kit.
Cytokine concentrations in each sample were determined with standard
curves of known concentrations of all five recombinant proteins. Samples
were read in a FACSCalibur flow cytometer (Becton Dickinson). The
detection limit of the assay was 0.5 pg/ml.
IF assays. Slides were prepared by collecting blood from BALB/c mice
infected with P. yoelii YM on day 5 postinfection (p.i.). Selection of ma-
ture stages of the parasite was performed with LS-MACS columns (Milte-
nyi Biotec), and thin blood smears were made, air dried, and stored until
immunofluorescence (IF) assay preparation and microscopy analysis. IF
assays were performed after the blood smears were fixed with ice-cold
acetone for 20 min and air dried. Well diameters were established with a
Dako-Pen (Dako), and blocking was performed by 30 min of incubation
at 37°C in PBS containing 3% BSA (USB). Pooled sera from the different
immunization groups and P. yoelii hyperimmune sera were diluted 1:100
in PBS supplemented with 3% BSA, applied to the slides, and incubated
for 1 h at 37°C. Slides were washed three times in PBS, incubated with
Alexa Fluor 568-conjugated goat anti-mouse IgG (Invitrogen) for 1 h at
37°C in the dark, washed three times in PBS, and then incubated with
DAPI (4=,6-diamidino-2-phenylindole, dihydrochloride; Invitrogen) di-
luted in ultrapure (Millipore) water for 10 min at room temperature.
After another round of washing, FluorSave (Calbiochem) was added and
the slides were sealed with coverslips. Parasites were visualized with a
Nikon TS100 epifluorescence microscope. P. yoelii hyperimmune sera
were obtained from BALB/c mice infected with P. yoelii 17XNL clone 1.1
(nonlethal strain) once a month for a total of 7 months. In parallel, to
confirm specificity, we also conducted IF assays with Leishmania ama-
zonensis promastigote forms (kindly donated by Selma Giorgio,
UNICAMP) and anti-rPyM2-MAEBL antisera.
Mouse challenge and parasitemia assessment. The levels of protec-
tion against blood-stage forms were determined by immunized mouse
survival of a lethal challenge via i.p. injection of 106 P. yoelii YM IE.
Parasitemia was monitored (see Fig. 2A) between 3 and 10 days p.i. by
counting at least 1,000 erythrocytes from thin blood smears stained with
the Panótico Rápido kit (Laborclin).
CD4 and CD8 T lymphocyte depletion. Groups of 15 C57BL/6J
mice were immunized (see Fig. 6A). Three weeks after the fourth dose, five
animals each were injected with 0.5 mg of anti-CD4 (clone GK1.5) or
anti-CD8 (clone YTS169.4) monoclonal antibody (BioXCell) for deple-
tion of the corresponding lymphocyte population. The in vivo depletion
efficacy of this antibody dose was determined in a preliminary experi-
ment, as assessed by flow cytometry of CD8 and CD4 T cells with
specific monoclonal antibodies recognizing different epitopes in the CD4
and CD8 molecules. As a control, five immunized animals were each
injected with 0.5 mg of purified unrelated mouse IgG (Sigma). On the
following day, animals were challenged with 106 P. yoelii YM IE (lethal
strain). The survival of animals was monitored and parasitemia was eval-
uated as described previously.
Ex vivo invasion assays of P. yoelii YM merozoites. To obtain high
levels of reticulocytes to be used as target cells in the invasion assay, re-
ticulocytemia was induced in groups of four to six naive mice by repeated
daily retro-orbital bleeding for 6 days. Leukocyte removal from the reticu-
locyte-enriched blood was achieved after two cycles of CF11 filtration
(33).
Infected erythrocytes were enriched and matured to schizonts. Enrich-
ment was achieved by bleeding P. yoelii YM-infected mice (n 3) on day
5 p.i. (60% parasitemia) and isolating mature forms (15 to 18 h of
development) by magnetic concentration as previously described (34). A
blood smear was made after the procedure to determine the concentration
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of parasites and verify the complete elimination of leukocytes. Next, to
synchronize parasites to at least 80% at the schizont stage, the pellet cor-
responding to the mature forms of P. yoelii was resuspended in McCoy’s
5A medium (Sigma) supplemented with glucose at 2.4 g/liter, gentamicin
(Sigma) at 40 mg/ml, and 20% human AB serum (UNICAMP blood
bank), inactivated, and allowed to adsorb to murine red blood cells, which
were cultivated for 3 to 6 h in 5% CO2 at 37°C for maturation.
Finally, invasion assays adapted from an assay for P. vivax (35) were
performed by mixing P. yoelii concentrated schizonts and target cells (en-
riched reticulocyte-rich blood) at a 1:10 ratio, corresponding to approxi-
mately 10% of the initial parasitemia. The mixture was diluted to a 4%
hematocrit in 100 l of McCoy’s 5A medium supplemented with 2.4
g/liter glucose and 40 mg/ml gentamicin and then cultured for approxi-
mately 20 h in a candle jar (36).
Immunized sera used in the invasion assays were heat inactivated by
incubation at 56°C for 40 min. Pooled sera from animals immunized with
four doses of rPyM2-MAEBL diluted 1:100 were added to the culture. As
controls, the pooled sera of animals injected four times with CFA and IFA
at the same dilution were used, and E64 (Sigma) at 100 M was used as a
positive inhibition control because it ensures no schizont rupture. As a
negative inhibition control, the assay was performed without the addition
of any drug or serum. Freshly infected erythrocytes were determined by
light microscopy, and parasitemia of young forms (rings and young tro-
phozoites) was determined as previously described. For details of the stan-
dardized methodology used for the P. yoelii invasion assays, see Fig. 7.
Statistical analysis. Survival curves of immunized animals after a le-
thal challenge were evaluated by the log-rank test. Comparison of the
means of three or more groups was performed by one-way analysis of
variance (ANOVA), and the statistical significance of differences between
two groups was assessed by the Bonferroni multiple-comparison test
when data assumed a Gaussian distribution, as assessed by the D’Agostino
and Pearson normality test. For samples with no Gaussian distribution,
group comparison was performed with the Kruskal-Wallis test, followed
by Dunn’s test. For assessment of the statistical significance of differences
between two groups, the Mann-Whitney U test was used. All tests were
performed with Prism GraphPad software version 5.0a. The results were
considered significant at P
 0.05.
RESULTS
Cloning and expression of the MAEBL M2 domain. The region
of the MAEBL M2 domain expressed as a recombinant bacterial
protein (rPyM2-MAEBL) is depicted in Fig. 1A. rPyM2-MAEBL
was expressed as an insoluble polypeptide and was therefore pu-
rified from the pellet after solubilization in buffer with 8 M urea
after several passages through a needle. SDS-PAGE analysis of the
purified product revealed a single band of approximately 45 kDa
(Fig. 1B). The recombinant protein generated (rPyM2-MAEBL)
was recognized by anti-histidine tag antibodies in the bacterial
pellet (Fig. 1C).
Immunogenicity of rPyM2-MAEBL in mice. Two groups of
mice (n 8 to 10) were immunized in accordance with the pro-
tocol described in Fig. 2A. Sera from immunized animals were
collected 3 weeks after each immunization, and antibody titers
against rPyM2-MAEBL were measured by ELISA. As shown in
Fig. 2B, the antibody titers obtained with one single dose of
rPyM2-MAEBL (log10 4.7 0.51) increased significantly after the
second dose in the rPyM2-MAEBL group (log10 6.0  0.15) and
remained high until the fourth dose (log10 6.2  0.17). As ex-
pected, no specific antibodies were detected in the serum of ani-
FIG 1 (A) Schematic representation and characterization of the gene for P. yoelii MAEBL. Abbreviations: S, signal peptide; C-Cys, cysteine-rich domain; TM,
transmembrane region; a.a., amino acids. (B) SDS-PAGE analysis of rPyM2-MAEBL. Lane M.W., molecular size markers (1). Detection of a 45-kDa band
corresponding to rPyM2-MAEBL. The lane was loaded with approximately 1g of protein and run through a 12% polyacrylamide gel. The gel was further stained
with Coomassie blue under denaturing conditions (2-mercaptoethanol). (C) Immunoblot analysis with anti-His antibodies confirms the expression of rPyM2-
MAEBL. After visualization on SDS-PAGE, rPyM2-MAEBL was transferred to a nitrocellulose membrane and immunoblot analysis was performed with anti-His
antibodies at a 1:1,500 dilution and goat anti-mouse IgG peroxidase antibodies.
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mals injected with adjuvant alone. These data demonstrate that
rPyM2-MAEBL is highly immunogenic in C57BL/6J mice.
Next, we determined the IgG subclass profile and the IgG1/
IgG2c ratio. As shown in Fig. 2C, mice immunized with the re-
combinant protein produced high titers of IgG1 (log10 5.9 0.32)
and IgG2c (log10 5.4  0.15), corresponding to an IgG1/IgG2c
ratio of 3.16. When tested by flow cytometry against various
MAEBL fragments expressed at the CHO cell surface (Fig. 3A),
anti-MAEBL IgM and IgG antibodies recognized different frag-
ments in the M2 region and the repeat region of MAEBL. It is
interesting that the IgM response was strongest against the M2
region (MAEBL-3 fragments) and the IgG response was strongest
against the repeat region (MAEBL-4 fragments) (Fig. 3B). As ex-
pected, no responses were observed against the MAEBL-5 frag-
ments, which encode the cysteine and transmembrane domains of
MAEBL and were not included in the MAEBL vaccine used in this
study.
We next performed IF assays to determine whether the anti-
bodies present in the sera of immunized mice recognized MAEBL
in its native form. As shown in Fig. 4, sera from immunized, but
not control, mice recognized P. yoelii schizont forms. P. yoelii-
hyperimmune sera recognized schizonts of P. yoelii, whereas
pooled sera from immunized mice did not recognize the promas-
tigote forms of the parasite L. amazonensis used as control for
specificity (data not shown).
Immunization with rPyM2-MAEBL protects against a chal-
lenge with blood-stage P. yoelii YM. In order to explore the
protective effect of anti-MAEBL antibodies, immunized ani-
mals were challenged with 106 blood-stage P. yoelii YM (lethal
strain) parasites 15 days after the last booster dose. As shown in
Fig. 5A, 75% of the animals that received only the adjuvant suc-
cumbed to the infection after 6 to 8 days. In contrast, 90% the
group immunized with rPyM2-MAEBL were significantly pro-
tected (P 0.0034). Moreover, the group of animals that received
the recombinant protein exhibited reduced parasite growth
(Fig. 5B), demonstrating lower parasitemia than the CFA and IFA
(Fig. 5C) group observed on day 5 p.i., the peak of parasitemia.
Replicates of immunization experiments were performed (see Fig.
S1 in the supplemental material).
CD4 cells are essential for protection.Protection against the
blood-stage forms of the parasite is mediated predominantly by
antibodies and CD4 T cells after vaccination with various anti-
genic formulations (37, 38). Thus, we investigated the involve-
ment of CD4 and CD8 T lymphocytes in the protection of
animals immunized with rPyM2-MAEBL before a challenge with
P. yoelii. To this end, 15 C57BL/6J mice were immunized with the
rPyM2-MAEBL protein in accordance with the protocol depicted
in Fig. 6A. Three weeks after the fourth dose, five animals immu-
nized with rPyM2-MAEBL were treated with depleting anti-CD4
or anti-CD8 monoclonal antibodies. The next day, the mice were
infected with 106 P. yoelii IE. Control animals (n  5) were in-
jected with purified rat IgG at the same concentration. As shown
in Fig. 6B, 100% of the CD4-depleted animals died between days
5 and 6 p.i. In contrast, animals depleted of CD8 cells or treated
with the IgG control exhibited the same levels of protection as
undepleted mice (Fig. 5).
To further characterize the cell-mediated immune response
induced by vaccination with rPyM2-MAEBL or with CFA and
IFA, splenocytes collected from immunized mice were cultured
in the presence of the rPyM2-MAEBL protein (1 or 10 g/ml)
for 18 h. A significant and specific level of cell proliferation was
observed in rPyM2-MAEBL splenocyte cultures stimulated
with 10 g/ml of the recombinant protein (Fig. 6C). Spleno-
cytes from animals injected with Freund’s adjuvant exhibited
lower proliferation levels when stimulated with the rPyM2-
MAEBL protein. As expected, cell stimulation with the mitogen
ConA led to strong, nonspecific proliferation in both groups.
Moreover, spleen cells harvested from mice immunized with
rPyM2-MAEBL secreted higher levels of IFN-	 after 120 h than
animals injected only with Freund’s adjuvant. Additionally, the
FIG 2 Immunogenicity of rPyM2-MAEBL. (A) Female C57BL/6J mice were immunized four times with 5g of rPyM2-MAEBL emulsified in CFA and IFA (1:1,
vol/vol) or only with the adjuvants (control group). (B) Induction of anti-MAEBL M2 total IgG responses in mice after the administration of priming and booster
doses. Pools of sera from immunized mice after each dose were quantified by ELISA, revealing high titers of antibodies (*, P
 0.05 [Kruskal-Wallis test]). (C)
IgG subclass determination in mice immunized with rPyM2-MAEBL. The results are expressed as the mean log of the antibody titer the standard deviation of
triplicates.
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amount of IFN-	 increased when we raised the concentration
of rM2-MAEBL used for stimulation with a maximum of
152.10 pg/ml when stimulated with 10 g/ml (Fig. 6D). The
same dose-dependent pattern was observed for the TNF dos-
age. Accordingly, after stimulation with 10g/ml protein, TNF
was detected at 638.38 pg/ml (Fig. 6E). Although the absolute
levels of IL-2 were low, with a maximum of 5.36 pg/ml, they
were higher than those of animals injected only with Freund’s
FIG 3 rPyM2-MAEBL-specific IgM and IgG antibodies generated in vaccinated mice recognized multiple epitopes in the MAEBL protein. (A) Localization of
various fragments of the MAEBL protein. These fragments were cloned into the pDisplay vector and expressed at the CHO cell surface after transfection. (B) Sera
from vaccinated mice were tested on transfected cells by flow cytometry. Serum response was calculated as defined in Materials and Methods. Responses above
the cutoff line of 20% were considered positive. *, P
 0.05; **, P
 0.005.
FIG 4 rPyM2-MAEBL-specific antibodies generated in vaccinated mice recognize the native protein expressed by P. yoelii. Fixed IFA slides of mature P. yoelii
schizonts were incubated with pooled sera from mice immunized as indicated in a 1:100 dilution. Bound IgG was stained with Alexa Fluor 568, and the parasite
nuclei were stained with DAPI.
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adjuvant (Fig. 6F). The levels of secreted IL-4 and IL-5 were
below the detection limit of the assay (data not shown).
Anti-MAEBLM2 antibodies inhibitP. yoeliimerozoite inva-
sion. Recently, Russell et al. designed a reliable assay to study P.
vivax invasion (35). Thus, to evaluate the inhibitory potential of
anti-PyM2-MAEBL antibodies against P. yoelii invasion of red
blood cells, we adapted this ex vivo invasion assay, which was
successfully used for P. vivax (35) (Fig. 7). To obtain blood con-
taining a high level of reticulocytes to be used in the invasion
assays important for P. yoelii YM parasites (39), groups of four to
six naive mice were bled daily to induce anemia and thus increase
the proportion of reticulocytes. Reticulocyte-rich blood was ob-
tained after 6 days of bleeding, reaching 46% 10% reticulocytes
(Fig. 8A). Next, this blood was mixed with heat-inactivated pooled
FIG 5 (A) Recombinant MAEBL M2 vaccine induces solid protection against a lethal challenge with P. yoelii YM. Mice from all of the immunized groups were
challenged with 1 106 P. yoelii YM IE 3 weeks after the fourth immunization. The percent survival and number of dead animals/total number of animals are
shown. rPyM2-MAEBL immunization protected 90% of the infected animals, in contrast to CFA and IFA administration (P 0.0034 [log-rank test]). (B, C)
Parasitemia levels (percent) of immunized mice were evaluated after infection with P. yoelii YM 3 weeks after the fourth dose in the control (C) and rPyM2-
MAEBL (B) groups. Immunization with rPyM2-MAEBL exhibited superior infection control and reduced parasite growth after infection with 106 P. yoelii IE. The
red lines represent animals that succumbed to the infection. (D) Summary of the mean parasitemia levels per group the standard deviation and P values. For
assessment of the statistical significance of differences between two groups, the Mann-Whitney U test was used. *, P 
 0.05; **, P 
 0.01; ns, no significant
difference.
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sera from immunized animals and a schizont preparation. As a
negative control for inhibition, the assay was performed in the
presence of nonimmune sera (CFA and IFA) or with medium
alone. As a positive control for inhibition and to validate our assay,
we added E64 to the culture mixture. E64 is a protease inhibitor
that has been shown to prevent schizont rupture and thus prevent
merozoite release and invasion. As expected, in E64-treated para-
sites, 94.91%  3.24% inhibition was observed (Fig. 8B). When
sera from animals immunized with rPyM2-MAEBL at a 1:100 di-
lution were used, up to 40% inhibition of merozoite invasion rel-
FIG6 CD4, but not CD8, T cells are essential for protection against a lethal challenge. (A) Five mice were immunized with rPyM2-MAEBL, and 3 weeks
after the fourth and final immunizing dose, they were injected with an anti-CD4 or anti-CD8 monoclonal antibody and on the following day were infected
with 106 P. yoelii IE. The control animals were injected with control IgG at the same concentration as the others. (B) Survival of immunized mice after CD4 or
CD8 lymphocyte depletion after a challenge with P. yoelii YM. The percent survival and number of dead animals/total number of animals are shown. Statistical
analysis was performed by the log-rank test: anti-CD4 versus IgG control,P 0.0039; anti-CD4 versus anti-CD8,P 0.0145. (C) Proliferation of cultured spleen
cells from vaccinated mice. Splenocytes were collected from immunized mice and cultured in the presence of the rPyM2-MAEBL protein (1 or 10g/ml) for 120
h. As a control, some wells received ConA (50 g/ml). T and B lymphocyte proliferation was assessed by the addition of [3H]TdR at 0.5 mCi/well. Tritium
incorporation was measured as radioactivity with the 1450 MicroBeta TriLux scintillation and luminescence counter (PerkinElmer). The results are expressed as
the average of triplicate cultures. Data are representative of three animals per group. Comparison of the means of the groups was done by one-way ANOVA,
followed by Bonferroni’s multiple-comparison test. **, P
 0.01; ***, P
 0.001. (D, E, F) The amounts of secreted cytokines in cell culture supernatants were
estimated with the BD CBA Th1/Th2 Mouse Cytokine kit. Concentrations of IFN-	 (D), TNF (E), and IL-2 (F) in each sample were determined by using standard
curves with known concentrations of all of the recombinants. The detection limit of the assay was 0.5 pg/ml. The results are expressed as the average of triplicate
cultures. Data are representative of three animals per group. Statistical analysis was performed with the Kruskal-Wallis test (no significant difference).
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ative to the control was observed. This inhibition was significant,
as no inhibition was observed when sera from mice injected with
CFA and IFA alone were used (Fig. 8B). We also tested sera with-
out complement heat inactivation and did not observe any differ-
ence in the invasion pattern (data not shown). This shows that
rPyM2-MAEBL-immunized mice produce antibodies that specif-
ically interfere with the invasion processes.
DISCUSSION
Here, we evaluated the immunogenic properties of a recombinant
protein based on the M2 domain of the P. yoelii MAEBL antigen.
We demonstrated that immunization with rPyM2-MAEBL emul-
sified in Freund’s adjuvant generated high levels of specific anti-
bodies capable of recognizing different epitopes in the recombi-
nant protein or its native form in parasite schizonts. These
antibodies were able to significantly inhibit P. yoelii merozoite
invasion ex vivo.
In vivo experiments revealed that immunization with four
doses of rPyM2-MAEBL was able to reduce the parasite load and
prevented death in 90% of the animals challenged with the lethal
P. yoelii YM strain. Although the immunization data presented in
this study correspond to a single experiment, we performed five
sets of immunization experiments. In three of them, we chal-
lenged mice (for the results, see Fig. S1 in the supplemental mate-
rial). As shown in Fig. S1A, three doses of rPyM2-MAEBL did not
induce a significant protective immune response (P  0.5431
[log-rank test]), in contrast to that seen in animals immunized
four times (see Fig. S1B and C in the supplemental material; P
0.0031 and P  0.0034 [log-rank test], respectively). Conse-
quently, we adopted the four-dose strategy in order to maximize
the immune response and to ensure that all of the animals had
similarly high-titer and mature antibodies. Previous results had
shown a similar effect, and it was noted that more booster doses
were more effective in generating high antibody levels that can be
maintained for long periods (40). Importantly, the proportions of
protection levels remained similar between the groups in two ex-
periments, demonstrating the reproducibility of the results (see
Fig. S1 in the supplemental material).
The finding that four immunizations were more effective in
terms of protection suggested a role for T cells. First, we observed
that immunization with rPyM2-MAEBL induced a T-cell re-
sponse that could be reproduced in vitro. Next, depletion experi-
ments demonstrated that CD4 but not CD8 cells were also
involved in protection. Our data point to a role for CD4 T cells,
but it should be noted that other cell types (i.e., NK T cells) can be
positive for the CD4 marker and thus maybe depleted by the
GK1.5 antibody that was used here. These cells have been shown
to have a role in innate immunity during the early phase of infec-
tion with rodent malaria parasites (41). Defining the role of the
CD4 cells involved in the protection conferred by rPyM2-MAEBL
is important and deserves further studies.
Because depletions were performed before a challenge, when
antibodies against rPyM2-MAEBL are already present in the sera
of immunized mice, our data indicate that both mechanisms may
be complementary for full protection. An analysis of the antibody
isotype profile revealed a balanced immune response, as IgG1 and
IgG2c were strongly induced and no significant differences among
the IgG subclasses were detected. Thus, this experiment could not
answer if immunization with rPyM2-MAEBL preferentially in-
duces a Th1- or Th2-type response. To explore this matter further,
five Th1/Th2 cytokine levels were measured simultaneously with
the BD CBA Th1/Th2 Mouse Cytokine kit. As a result, we detected
larger amounts of Th1 cytokines (IFN-	 and IL-2). IL-4 and IL-5
were not detected.
FIG 7 Overview of the P. yoelii ex vivo invasion assay methodology used in this study. Thin smears stained with new methylene blue (B) or Giemsa (C, D, F, G),
illustrating the key methodological steps of the ex vivo P. yoelii invasion assay. (A) Blood from reticulocyte donator animals contained a mixture of normocytes,
reticulocytes (35 to 50%), and leukocytes. (B) Reticulocyte-rich blood was collected and submitted to two rounds of filtration on a CF-11 cellulose column for
leukocyte depletion. (C) Thin smears demonstrating different stages of parasite maturation typically observed on asynchronous infections with P. yoelii. (D)
Infected animals were bled on days 5 and 6 p.i. and submitted to an enrichment protocol through midi-MACS LS columns. Enriched parasites were matured for
3 to 6 h. Concentrated reticulocyte target cells (B) and mature P. yoelii schizonts (D) were mixed at a ratio of 1:10 for the invasion assay (E). After culturing for
20 h, the invasion assay mixture reveals remnants of ruptured schizonts (asterisks) and newly invaded red blood cells (arrows) (F, G).
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Little is known about the invasion pathways of P. yoelii, mainly
because of the absence of a robust ex vivo invasion assay. To date,
the elucidation of the P. yoelii invasion process has been limited to
complicated and time-consuming in vivo assays (42). Here we
present a simple ex vivo assay to study the process of P. yoelii
invasion that could be helpful in assessing the steps involved in
parasite adhesion to and invasion of red blood cells, thereby cre-
ating/adapting an important methodology to validate antibodies
able to inhibit parasite invasion, a crucial strategy in vaccine de-
sign. The invasion assay developed allowed us to test the ability of
rPyM2-MAEBL antibodies to inhibit the invasion of red blood
cells by P. yoelii YM. Sera from animals immunized with rPyM2-
MAEBL were able to inhibit invasion by blood-stage forms of P.
yoelii YM up to 40%. The fact that complete inhibition of invasion
by rPyM2-MAEBL antisera was not obtained can be explained by
the possibility that either only a subset of the antibodies induced
was inhibitory or those merozoites use multiple pathways to in-
vade red blood cells. The latter possibility is supported by data
from previous experiments in which MAEBL knockout P. berghei
ANKA parasites were still able to invade red blood cells in vivo
(43). Also, in vitro invasion assays never show complete inhibition
(44, 45) but still point to an inhibitory potential of the developed
antibody. From our experiments, it is not clear if MAEBL func-
tions in the primary attachment of merozoites to the red blood cell
membrane or in later steps, when the tight junction has been
formed.
Although MAEBL was first described in blood-stage merozo-
ites (23), its expression was also detected in midgut and salivary
gland sporozoites (26, 46, 47). In addition, antibodies capable of
recognizing the P. yoelii MAEBL antigen also inhibit parasite de-
velopment in primary hepatocyte cultures (28). It is also possible
that MAEBL contains T-cell epitopes, which may be targetable on
infected liver cells. Therefore, MAEBL appears to be strongly as-
sociated with protection and may present a promising candidate
for a multistage vaccine comprising several components. The data
presented here set the foundation for the exploration of M2 do-
main-based vaccines with other adjuvants and immunization reg-
imens alone or in combination with other malaria antigens for the
development of an efficient malaria vaccine.
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